Sentences with phrase «in patients with macular degeneration»
For example, a consortium of research groups called the London Project to Cure Blindness aims to test RPE transplants from embryonic stem cells in patients with macular degeneration this year.
https://www.scientificamerican.com/ Not exact matches
The study included 18 patients, half with age - related macular degeneration and half with Stargardt's macular dystrophy, the leading causes of blindness in adults and juveniles.
In July Genentech announced that the drug Lucentis stabilized or even improved vision in a yearlong clinical trial of patients with so - called wet macular degeneration, a form that involves overgrowth of blood vesselIn July Genentech announced that the drug Lucentis stabilized or even improved vision in a yearlong clinical trial of patients with so - called wet macular degeneration, a form that involves overgrowth of blood vesselin a yearlong clinical trial of patients with so - called wet macular degeneration, a form that involves overgrowth of blood vessels.
«For example, patients with Alzheimer's get protein deposits in the brain, and we can see similar deposits in the backs of the eyes of patients who have macular degeneration,» said Friedlander.
Researchers only discovered this process in the late 1990s, but they've already begun dozens of clinical trials to gauge whether infusing patients with these small RNAs works against a range of diseases, from lung infections to liver cancer to age - related macular degeneration, a sight - stealing condition that mainly affects people over the age of 50.
Researchers are hopeful that implantable miniature telescopes will usher in successful treatment for patients with age - related macular degeneration.
The 206 patients in the study shared a number of characteristics, including stable, untreatable, age - related macular degeneration in both eyes with visual acuity no better than 20/80 but no worse than 20/800, along with good peripheral vision.
In 2011, the FDA approved Regeneron's Eylea (aflibercept), an antibody fragment that helps maintain vision in patients with wet age - related macular degeneratioIn 2011, the FDA approved Regeneron's Eylea (aflibercept), an antibody fragment that helps maintain vision in patients with wet age - related macular degeneratioin patients with wet age - related macular degeneration.
Any breakthrough in this area could be of immediate benefit to thousands of patients with macular degeneration.
Age - related macular degeneration is extremely prevalent, with as many as one in 10 patients over the age of 65 affected to some degree.
Roughly 20 percent of patients with age - related macular degeneration suffer from abnormal blood vessel growth and vascular leakage, says Campochiaro, and so may be helped by this new therapy, if it proves to work in clinical trials.
It is important for all patients (and family members of patients) with macular degeneration to know that although the disease can injure the central vision of both eyes severely enough to render one «legally blind,» it is extremely uncommon to cause complete blindness in even a single eye.
In 1997, the mainstays of therapy for patients with macular degeneration include daily monitoring of the integrity of their central vision (usually by viewing a simple printed grid) as well as periodic visits to their eye doctor.
In fact, although only 10 percent of patients develop new blood vessels, this complication is responsible for most of the legal blindness associated with macular degeneration.
Central visual field loss, a scotoma or blind area in central vision, is found most commonly in patients with age - related macular degeneration (AMD).
«We found that intensive doses of statins carry the potential for clearing up the lipid debris that can lead to vision impairment in a subset of patients with macular degeneration,» said Joan W. Miller, M.D., the Henry Willard Williams Professor and Chair of Ophthalmology at Harvard Medical School and Chief of Ophthalmology at Massachusetts Eye and Ear and Massachusetts General Hospital.
Researchers at Massachusetts Eye and Ear / Harvard Medical School and the University of Crete have conducted a phase I / II clinical trial investigating the efficacy of statins (cholesterol - lowering medications) for the treatment of patients with the dry form of age - related macular degeneration (AMD)-- the leading cause of blindness in the developed world.
The researchers detected RPE cells in the eye of the patient with Stargardt disease but not in the patient with age - related macular degeneration.
A case review recently published in The New England Journal of Medicine describes how three elderly patients with macular degeneration were blinded after they were treated at a Florida clinic (FL, USA).
«This is the first human trial of this novel stem cell - based implant, which is designed to replace a single - cell layer that degenerates in patients with dry age - related macular degeneration,» says lead author and surgeon for the study Dr. Amir H. Kashani, assistant professor of clinical ophthalmology at the Keck School of Medicine of USC.
While undergoing treatment in what was described as a clinical trial, three elderly patients with macular degeneration were blinded after being administered a treatment based on autologous adipose tissue.
hESC - derived RPE were transplanted in four Asian patients: two with dry age - related macular degeneration and two with Stargardt's macular dystrophy.
A pilot study assessing the safety and feasibility of the transplantation of autologous iPSC - derived retinal pigment epithelium (RPE) cell sheets in patients with exudative (wet - type) age - related macular degeneration was launched in Japan in August 2013.
Lanza's team figured out how to coax stem cells taken from human embryos into becoming the RPE cells that die off along with photoreceptors in macular degeneration, and in 2011 the team began injecting these manufactured cells into patients» eyes.
They were financed by Advanced Cell Technology, a biotech company with laboratories in Marlborough, Massachusetts, that recently won approval from the U.S. Food and Drug Administration to test the treatment in 24 patients suffering from either dry advanced macular degeneration, or a juvenile form of the disease known as Stargardt's.
• Emory University Hospital Department of Radiology — The utilization of CT imaging in patients who present to the emergency department with acute abdominal pain, 2005 — 2007 • Emory University Hospital Department of Radiology — CTA for the pre-operative evaluation of living related liver donors, 2001 — 2001 • Emory University Hospital Department of Geriatrics — Transferring behavior research into nursing home practice (this study is prospective and is being funded by the National Institute on Aging), 2000 — 2002 • CTA for the Pre-Operative Evaluation of Living Related Liver Donors: A Comparison of Multi-Detector CT and Digital Subtraction Angiography, Radiological Society of North America, 2001 • Characteristics of Age - Related Macular Degeneration Patients with Low Vision Receiving Visual Rehabilitation, American Academy of Ophthalmology and the Journal of Rehabilitation Research and Developmepatients who present to the emergency department with acute abdominal pain, 2005 — 2007 • Emory University Hospital Department of Radiology — CTA for the pre-operative evaluation of living related liver donors, 2001 — 2001 • Emory University Hospital Department of Geriatrics — Transferring behavior research into nursing home practice (this study is prospective and is being funded by the National Institute on Aging), 2000 — 2002 • CTA for the Pre-Operative Evaluation of Living Related Liver Donors: A Comparison of Multi-Detector CT and Digital Subtraction Angiography, Radiological Society of North America, 2001 • Characteristics of Age - Related Macular Degeneration Patients with Low Vision Receiving Visual Rehabilitation, American Academy of Ophthalmology and the Journal of Rehabilitation Research and DevelopmePatients with Low Vision Receiving Visual Rehabilitation, American Academy of Ophthalmology and the Journal of Rehabilitation Research and Development, 1998